8,485 reports of this reaction
7.2% of all LEVETIRACETAM ORAL reports
#2 most reported adverse reaction
SEIZURE is the #2 most commonly reported adverse reaction for LEVETIRACETAM ORAL, manufactured by Amneal Pharmaceuticals LLC. There are 8,485 FDA adverse event reports linking LEVETIRACETAM ORAL to SEIZURE. This represents approximately 7.2% of all 117,347 adverse event reports for this drug.
Patients taking LEVETIRACETAM ORAL who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is moderately reported among LEVETIRACETAM ORAL users, representing a notable but not dominant share of adverse events.
In addition to seizure, the following adverse reactions have been reported for LEVETIRACETAM ORAL:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 8,485 FDA reports for LEVETIRACETAM ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 7.2% of all adverse event reports for LEVETIRACETAM ORAL, making it one of the most commonly reported side effect.
If you experience seizure while taking LEVETIRACETAM ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.